

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1645 1644

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C. C.	4,816,567	03/28/1989	Cabilly et al.			
	5,264,365	11/23/1993	Georgiou et al.			
	5,264,586	11/23/1993	Nicolaou et al.			
	5,348,876	09/20/1994	Michaelsen et al.			
	5,500,362	03/19/1996	Robinson et al.			
	5,508,192	04/16/1996	Georgiou et al.			
	5,585,097	12/17/1996	Bolt et al.			
	5,624,821	04/29/1997	Winter et al.			
	5,639,635	06/17/1997	Joly et al.			
	5,648,237	07/15/1997	Carter			
	5,821,337	10/13/1998	Carter et al.			
	5,840,523	11/24/1998	Simmons et al.			
	5,854,027	12/29/1998	Steipe et al.			
	5,892,019	04/06/1999	Schlom et al.			
	6,027,888	02/22/2000	Georgiuo et al.			
	6,083,715	07/04/2000	Georgiuo et al.			
	6,165,745	12/26/2000	Ward et al.			
	6,455,279 B1	09/24/2002	Ambrosius et al.			
C. C.	6,602,688 B1	08/05/2003	Opper et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
C. C.	WO 92/22583	12/23/1992	PCT				
C. C.	WO 94/29531	12/22/1994	PCT				
C. C.	WO 95/14779	06/01/1995	PCT				

EXAMINER ej	DATE CONSIDERED 6/19/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1045 1644

C. C.	WO 99/25378	05/27/1999	PCT				
	WO 99/51642	10/14/1999	PCT				
	WO 99/64460	12/16/1999	PCT				
	WO 02/056910	07/25/2002	PCT				
C. C.	WO 02/061090	08/08/2002	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
C. C.		Adlersberg, "The Immunoglobulin Hinge (Interdomain) Region", <i>Ric. Clin. Lab.</i> , 6(3):191-205 (1976)					
		Aric et al., "Chaperone function of FkpA, a heat shock prolyl isomerase, in the periplasm of <i>Escherichia coli</i> ", <i>Molecular Microbiology</i> , 39(1):199-210 (2001)					
		Armour et al., "Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities", <i>Eur. J. Immunol.</i> , 29:2613-2624 (1999)					
		Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity", <i>Proc. Nat. Acad. Sci. USA</i> , 91:3809-3813 (1994)					
		Bloom et al., "Intrachain disulfide bond in the core hinge region of human IgG4", <i>Protein Science</i> , 6:407-415 (1997)					
		Bothmann et al., "The Periplasmic <i>Escherichia coli</i> Peptidylprolyl <i>cis,trans</i> -Isomerase FkpA", <i>Journal of Biological Chemistry</i> , 275(22):17100-17105 (2000)					
		Brekke et al., "Activation of complement by an IgG molecule without a genetic hinge", <i>Nature</i> , 363:628-630 (1993)					
		Capel et al., "Heterogeneity of Human IgG Fc Receptors", <i>Immunomethods</i> , 4:25-34 (1994)					
		Carter et al., "High Level <i>Escherichia Coli</i> Expression and Production of a Bivalent Humanized Antibody Fragment", <i>Bio/Technology</i> , 10:163-167 (1992)					
		Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy", <i>Proc. Natl. Acad. Sci. USA</i> , 89:4285-4289 (1992)					
		Chamow et al., "A Humanized, Bispecific Immunoadhesin-Antibody that Retargets CD3 ⁺ Effectors to Kill HIV-1-Infected Cells", <i>J. Immunol.</i> , 153:4268-4280 (1994)					
		Chang et al., "High-level secretion of human growth hormone by <i>Escherichia coli</i> ", <i>Gene</i> , 55:189-196 (1987)					
		Chen et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen", <i>J. Mol. Biol.</i> , 293:865-881 (1999)					
		Chen et al., "Chaperone Activity of DsbC", <i>Journal of Biological Chemistry</i> , 274(28):19601-19605 (1999)					
C. C.		Chothia et al., "Canonical Structures for the Hypervariable Regions", <i>J. Mol. Biol.</i> , 196:901-917 (1987)					

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	6/19/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1645 1644

C.C.	Clynes et al., "Fc receptors are required in passive and active immunity to melanoma", <i>Proc. Natl. Acad. Sci. USA</i> , 95:652-656 (1998)
	Daëron et al., "Fc Receptor Biology", <i>Annu. Rev. Immunol.</i> , 15:203-234 (1997)
	de Haas et al., "Fcγ receptors of phagocytes", <i>J. Lab. Clin. Med.</i> , 126:330-341 (1995)
	Duncan et al., "The binding site for Clq on IgG", <i>Nature</i> , 232:738-740 (1988)
	Friend et al., "Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection", <i>Transplantation</i> , 68:1632-1637 (1999)
	Guyer et al., "Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors", <i>J. Immunol.</i> , 117:587-593 (1976)
	Hara et al., "Overproduction of Penicillin-Binding Protein 7 Suppresses Thermosensitive Growth Defect at Low Osmolarity due to an <i>spr</i> Mutation of <i>Escherichia coli</i> ", <i>Microbial Drug Resistance</i> , 2(1):63-72 (1996)
	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity: Mimicking Affinity Maturation", <i>J. Mol. Biol.</i> , 226:889-896 (1992)
	Humphreys et al., "Formation of dimeric Fabs in <i>Escherichia coli</i> : effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions", <i>J. Immunol. Methods</i> , 209:193-202 (1997)
	Isaacs et al., "A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans", <i>Clin. Exp. Immunol.</i> , 106:427-433 (1996)
	Jackson et al., "In Vitro Antibody Maturation: Improvement of a High Affinity, Neutralizing Antibody Against IL-1β", <i>J. Immunol.</i> , 154(7):3310-3319 (1995)
	Joly et al., "Overexpression of <i>Escherichia coli</i> oxidoreductases increases recombinant insulin-like growth factor-I accumulation", <i>Proc. Natl. Acad. Sci. USA</i> , 95:2773-2777 (1998)
	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", <i>Nature</i> , 321:522-525 (1986)
	Kelley et al., "Analysis of the Factor VIIa Binding Site on Human Tissue Factor: Effects of Tissue Factor Mutations on the Kinetics and Thermodynamics of Binding", <i>Biochemistry</i> , 10383-10392 (1995)
	Kikuchi et al., "The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (<i>phoA</i>) of <i>Escherichia coli</i> ", <i>Nucleic Acids Res.</i> , 9:5671-5678 (1981)
	Kim et al., "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor", <i>J. Immunol.</i> , 24:2429-2434 (1994)
	Kim et al., "Evidence that the Hinge Region Plays a Role in Maintaining Serum Levels of the Murine IgG1 Molecule", <i>Mol. Immunol.</i> , 32(7):467-475 (1995)
	Kipriyanov et al., "Generation of Recombinant Antibodies", <i>Mol. Biotech.</i> , 12:173-201 (1999)
C.C.	Lee et al., "Characterization of the Gene Encoding Heat-Stable Toxin II and Preliminary Molecular Epidemiological Studies of Enterotoxigenic <i>Escherichia coli</i> Heat-Stable Toxin II Producers", <i>Infect. Immun.</i> , 42(1):264-268 (1983)

EXAMINER <i>ca of</i>	DATE CONSIDERED 6/19/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	


FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1645 1644


C.C.	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", <i>BioTechnology</i> , 10:779-783 (1992)
	Merchant et al., "An efficient route to human bispecific IgG", <i>Nat. Biotech.</i> , 16:677-681 (1998)
	Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region dimmers", <i>Proc. Natl. Acad. Sci USA</i> , 81(21):6851-6855 (1984)
	Peters et al., "Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth", <i>Proc. Natl. Acad. USA</i> , 90:8915-8919 (1993)
	Picken et al., "Nucleotide Sequence of the Gene for Heat-Stable Enterotoxin II of <i>Escherichia coli</i> ", <i>Infect. Immun.</i> , 42(1):269-275 (1983)
	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments", <i>Immunotech</i> , 3:83-105 (1997)
	Plückthun et al., "Producing antibodies in <i>Escherichia coli</i> : from PCR to fermentation", <i>Antibody Engineering: A Practical Approach</i> , Oxford Press, Chap. 10, pp. 203-252 (1996)
	Plückthun, "Antibodies from <i>Escherichia coli</i> ", <i>The Pharmacol. of Monoclonal Antibodies, Handbook of Exp. Pharmacology</i> , 3:269-315 (1994)
	Presta et al., "Humanization of an Anti-Bascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders", <i>Cancer Res.</i> , 57:4593-4599 (1997)
	Presta et al., "Humanization of an Antibody Directed Against IgE", <i>J. Immunol.</i> , 151(5):2623-2632 (1993)
	Presta et al., "Generation of a Humanized, High Affinity Anti-tissue Factor Antibody for Use as a Novel Antithrombotic Therapeutic", <i>Thromb. Haemost.</i> , 85:379-389 (2001)
	Presta, "Antibody Engineering", <i>Curr. Op. Struct. Biol.</i> , 2:593-596 (1992)
	Proba et al., "Functional antibody single-chain fragments from the cytoplasm of <i>Escherichia coli</i> : influence of thioredoxin reductase (TrxB)", <i>Gene</i> , 159:203-207 (1995)
	Ramm et al., "The Periplasmic <i>Escherichia coli</i> Peptidylprolyl <i>cis,trans</i> -Isomerase FkpA", <i>J. Mol. Biol.</i> , 275(22):17106-17113 (2000)
	Ravetch et al., "Fc Receptors", <i>Annu. Rev. Immunol.</i> , 9:457-492 (1991)
	Reddy et al., "Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4", <i>J. Immunol.</i> , 164:1925-1933 (2000)
	Riechmann et al., "Reshaping human antibodies for therapy", <i>Nature</i> , 332:323-327 (1988)
	Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis", <i>Gene</i> , 169:147-155 (1995)
	Scholtissek et al., "A cloning cartridge of γ_t terminator", <i>Nucleic Acids Res.</i> , 15:3185 (1987)
C.C.	Sheilds et al., "High Resolution Mapping of the Binding Site on Human IgG1 for Fc γ R1, Fc γ RII, Fc γ RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc γ R", <i>Biol. Chem.</i> , 276, 6591-6604 (2001)

EXAMINER <i>ec</i>	DATE CONSIDERED <i>6/19/06</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1645 1644

C.C.		Siebenlist et al., "E. coli RNA Polymerase Interacts Homologously with Two Different Promoters", <i>Cell</i> , 20:269-281 (1980)
		Simmons et al., "Expression of full-length immunoglobulins in <i>Escherichia coli</i> " rapid and efficient production of aglycosylated antibodies", <i>J. Immunol. Methods</i> , 263:133-147 (2002)
		Simmons et al., "Translational level is a critical factor for the secretion of heterologous proteins in <i>Escherichia coli</i> ", <i>Nature Biotechnology</i> , 14:629-634 (1996)
		Sims et al., "A Humanized CD18 Antibody Can Block Function without Cell Destruction", <i>J. Immunol.</i> , 151:2296-2308 (1993)
		Sutcliffe, "Complete Nucleotide Sequence of the <i>Escherichia coli</i> Plasmid pBR322", <i>DNA: Replication and Recombination, Cold Spring Harbor Symposia on Quantitative Biology, Cold Spring Harbor Laboratory</i> , Vol. XLIII:77-90 (1979)
		Thompson et al., "A fully human antibody neutralizing biologically active human TGF β 2 for use in therapy", <i>J. Immunol Meth</i> , 227:17-29 (1999)
		Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", <i>Science</i> , 239:1534-1536 (1988)
		Yanofsky et al., "The complete nucleotide sequence of the tryptophan operon of <i>Escherichia coli</i> ", <i>Nucleic Acids Res.</i> , 9:6647-6668 (1981)
		Yansura et al., "Nucleotide Sequence Selection for Increased Expression of Heterologous Genes in <i>Escherichia coli</i> ", <i>Methods: A companion to Methods in Enzymology</i> , 4:151-158 (1992)
C.C.		Yelton et al., "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis", <i>J. Immunol.</i> , 155:1994-2004 (1995)

EXAMINER 	DATE CONSIDERED 6/19/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

	INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 11669.195USUI	Application Number: 10/697,995
			Applicant: REILLY ET AL.	
			Filing Date: 10/30/2003	Group Art Unit: UNKNOWN 1644


U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C. C.	5,677,425	10/14/1997	BODMER ET AL.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C. C.		Davis, A. et al., "Intermolecular disulfide bonding in IgM: effects of replacing cysteine residues in the μ heavy chain", <u>The EMBO Journal</u> , 8(9):2519-2526 (1989)
C. C.		Pack, P. et al., "Miniantibodies: Use of Amphipathic Helices to Produce Functional, Flexibly Linked Dimeric F _v Fragments with igh Avidity in <i>Escherichia coli</i> ", <u>Biochemistry</u> , 31(6):1579-1584 (Feb. 18, 1992)
C. C.		Copy of International Search Report dated May 27, 2004
C		

23552

PATENT TRADEMARK OFFICE

EXAMINER 	DATE CONSIDERED 6/29/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1643 1644

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	5,648,260	07/15/1997	Winter et al.	X	X	
	5,731,168	03/24/1998	Carter et al.			
	5,807,706	09/15/1998	Carter et al.			
	5,821,333	10/13/1998	Carter et al.			
	6,331,415 B1	12/18/2001	CABILLY ET AL.			
	2005/0048572 A1	03/03/2005	Reilly et al.			
C.C.	2005/0152894 A1	07/14/2005	Krumrien et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
C.C.	WO 89/01974	03/09/1989	PCT				
C.C.	WO 04/042017 A2	05/21/2004	PCT				
C.C.	WO 05/027966 A2	03/31/2005	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
C.C.	Aruffo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" Cell 61:1303-1313 (Jun 29, 1990)
	Ashkenazi et al., "Immunoadhesins" Intern. Rev. Immunol. 10:219-227 (1993)
	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" Proc. Natl. Acad. Sci. 88:10535-10539 (Dec 1991)
	Atwell et al., "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library" J.Mol.Biol. 270(1):26-35 (1997)
	Bennett et al., "Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors. Hormone Pharmacology and Application to Solid Phase Screening of Synthetic Peptide Antisera" The Journal of Biological Chemistry 266(34):23060-23067 (1991)
	Berg et al., "Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain" Proc. Natl. Acad. Sci. USA 88:4723-4727 (June 1991)
	Brekke O H et al., "The structural requirements for complement activation by IgG: does it hinge on the hinge?" Immunol Today 16(2):85-90 (Feb 1995)
C.C.	Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin Gsub1/nor fragments" Science 229:81-83 (July 5, 1985)

EXAMINER <i>h g</i>	DATE CONSIDERED <i>6/19/06</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USUI	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 4645 1644

C.C.	Byrn et al., "Biological Properties of a CD4 Immunoaderhin" Nature 344:667-670 (April 12, 1990)
	Canevari et al., "Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody" J Natl Cancer Inst. 87(19):1463-1469 (Oct 4, 1995)
	Capon et al., "Designing CD4 Immunoaderhins for AIDS Therapy" Nature 337:525-531 (Feb 9, 1989)
	Carpenter et al., "Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated T Cells" J. Immunol. 165:6205-6213 (2000)
	Carter, "Bispecific human IgG by design" J Immunol Methods 248(1-2):7-15 (Feb 1, 2001)
	Chalupny et al., "T-cell activation molecule 4-1BB binds to extracellular matrix proteins" Proc. Natl. Acad. Sci. USA 89(21):10360-10364 (Nov 1992)
	Cunningham and Wells, "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis" Science 244:1081-1085 (Jun 2, 1989)
	Dietsch et al., "Bispecific Receptor Globulins, Novel Tools for the Study of Cellular Interactions" Journal of Immunological Methods 162:123-132 (1993)
	Duncan et al., "Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG." Nature 332:563-564 (Apr 7, 1988)
	Ellman et al., "Biosynthetic Method for Introducing Unnatural Amino Acids Site-Specifically into Proteins" Meth. Enzym. 202:301-336 (1991)
	Fanger et al., "Bispecific Antibodies" Critical Reviews in Immunology 12(3,4):101-124 (1992)
	Gascoigne et al., "Secretion of a chimeric T-cell receptor-immunoglobulin protein" Proc Natl Acad Sci U S A. 84(9):2936-2940 (May 1987)
	Gazzano-Santoro et al., "A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody" Journal of Immunological Methods. 202(2):163-171 (Mar 28, 1997)
	Gillies et al., "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities" Hum. Antibod. Hybridomas 1(1):47-54 (1990)
	Gruber et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in Escherichia coli" Journal of Immunology 152:5368-5374 (1994)
	Hammerling et al., "Use of hybrid antibody with anti-VI47G and anti-ferritin specificities in locating cell surface antigens by electron microscopy" Journal of Experimental Medicine 128:1461-1469 (1968)
	Harris, "Production of humanized monoclonal antibodies for in vivo imaging and therapy" Biochemical Society Transactions 23:1035-1038 (1995)
	Hayden et al., "Antibody engineering" Curr Opin Immunol. 9(2):201-212 (Apr 1997)
C.C.	Hollinger et al., "Diabodies": Small Bivalent and Bispecific Antibody Fragments" Proc. Natl. Acad. Sci. USA 90:6444-6448 (Jul 1993)

EXAMINER <i>u</i> <i>CS</i>	DATE CONSIDERED 6/19/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1643 1644

C - C	Hsieh-Ma et al., "In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III" Cancer Research 52(24):6832-6839 (Dec 15, 1992)
	Hsu et al., "A Humanized Anti-CD3 Antibody, HuM291, With Low Mitogenic Activity, Mediates Complete And Reversible T-Cell Depletion in chimpanzees" Transplantation 68(4):545-554 (1999)
	Hurle and Gross, "Protein Engineering Techniques for Antibody Humanization" Curr. Op. Biotech. 5:428-433 (1994)
	Idusogie et al., "Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc" J. Immunol. 164(8):4178-4184 (2000)
	Jefferis et al., "Glycosylation of antibody molecules: structural and functional significance" Chem. Immunol. 65:111-128 (1997)
	Jefferis et al., "IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation" Immunol Rev. 163:59-76 (1998)
	Jefferis et al., "Interaction sites on human IgG-Fc for Fc gamma R: current models" Immunol. Lett. 82(1-2):57-65 (2002)
	Karpovsky et al., "Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies" J Exp Med. 160(6):1686-1701 (Dec 1, 1984)
	Klein et al., "Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region" Proc. Natl. Acad. Sci. USA 78(1):524-528 (Jan 1981)
	Kon et al., "Randomised, dose-ranging, placebo-controlled study of chimeric Antibody to CD4 (keliximab) in Chronic Severe Asthma" Lancet 352:1109-1113 (1998)
	Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" Journal of Immunology 148(5):1547-1553 (Mar 1, 1992)
	Kroesen et al., "Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells" Cancer Immunol Immunother. 37(6):400-407 (Nov 1993)
	Kroesen et al., "Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2" Br J Cancer 70(4):652-661 (Oct 1994)
	Kufer et al., "A revival of bispecific antibodies" Trends Biotechnol. 22(5):238-244 (May 2004)
	Kurschner et al., "Construction, purification, and characterization of new interferon γ (IFN γ) inhibitor proteins. Three IFN γ receptor-immunoglobulin hybrid molecules" Journal of Biological Chemistry 267(13):9354-9360 (1992)
	Le Doussal et al., "Bispecific Monoclonal Antibody-Mediated Targeting of an Indium-111-Labeled DTPA Dimer to Primary Colorectal Tumors: Pharmacokinetics, Biodistribution, Scintigraphy and Immune Response" J. Nucl. Med. 34:1662-1671 (1993)
	Le Doussal et al., "Bispecific-Antibody-Mediated Targeting of Radiolabeled Bivalent Haptens: Theoretical, Experimental and Clinical Results" Int. J. Cancer Suppl. 7:58-62 (1992)
	Lesslauer et al., "Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-induced Lethality" European Journal of Immunology 21:2883-2886 (1991)
C - C	Linsley et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation" J Exp Med. 173(3):721-730 (Mar 1, 1991)

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	6/19/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1643 1644

C.C.	Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7" J Exp Med. 174(3):561-569 (Sep 1, 1991)
	Lisowska, "The role of glycosylation in protein antigenic properties" Cell. Mol. Life Sci. 59(3):445-455 (2002)
	Michaelsen T E et al., "One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge" Proc Natl Acad Sci U S A. 91(20):9243-9247 (Sep 27, 1994)
	Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" Nature 305:537-540 (Oct 6, 1983)
	Mimura et al., "The molecular specificity of IgG-Fc interactions with Fc gamma receptors" Adv. Exp. Med. Biol. 495:49-53 (2001)
	Muller et al., "The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies" FEBS Letters 422(2):259-264 (Jan 30, 1998)
	Nolan et al., "Bifunctional antibodies: concept, production and applications" Biochimica et Biophysica Acta 1040:1-11 (1990)
	Noren et al., "A general method for site-specific incorporation of unnatural amino acids into proteins" Science 244(4901):182-188 (Apr 14, 1989)
	Peipp & Valerius, "Bispecific antibodies targeting cancer cells" Biochem Soc Trans. 30(4):507-511 (Aug 2002)
	Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity" Journal of Experimental Medicine 174:1483-1489 (Dec 1991)
	Perez et al., "Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody", Nature 316:354-256 (1985)
	Ponder and Richards, "Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes" J Mol Biol. 193(4):775-791 (Feb 20, 1987)
	Presta, "Engineering antibodies for therapy" Current Pharmaceutical Biotechnology 3(3):237-256 (2002)
	Radaev et al., "Recognition of immunoglobulins by Fc gamma receptors" Molecular Immunology 38(14):1073-1083 (2001)
	Ridgway and Gorman, "Expression and Activity of IgE Receptor Alpha Chain-IgG Chimeric Molecules" Journal of Cell Biology 115:250a (Abstract No. 1448) (1991)
	Rodrigues et al., "Engineering a humanized bispecific F(ab') ₂ fragment for improved binding to T cells" Int. J. Cancer (Suppl.) 7:45-50 (1992)
	Rudd et al., "Glycosylation and the Immune System" Science 291:2370-2376 (2001)
	Segal et al., "Introduction: Bispecific Antibodies" J Immunol Methods 248(1-2):1-6 (Feb 1, 2001)
	Segal et al., "Targeting and Activation of Cytotoxic Lymphocytes" Chem. Immunol. 47:179-213 (1989)
	Shalaby, et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" Journal of Experimental Medicine 175:217-225 (Jan 1992)
	Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease" Clin. Exp. Immunol. 79:315-321 (1990)
C.C.	Stamenkovic et al., "The B Lymphocyte Adhesion Molecule CD22 Interacts with Leukocyte Common Antigen CD45RO on T Cells and \1412-6 Sialyltransferase, CD75, on B Cells" Cell 66:1133-1144 (Sep 20, 1991)

EXAMINER <i>ca</i> <i>cs</i>	DATE CONSIDERED <i>6/19/06</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1643 1644

C.C.	Stickney et al., "Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma" Cancer Research 51:6650-6655 (Dec 15, 1991)
	Talac & Nelson, "Current perspectives of bispecific antibody-based immunotherapy" J Biol Regul Homeost Agents 14(3):175-181 (Jul 2000)
	Traunacker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" Nature 339:68-70 (May 4, 1989)
	Valone et al., "Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu" J Clin Oncol. 13(9):2281-2292 (Sep 1995)
	Van der Lubbe et al., "Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis" Arthritis and Rheumatism 36(10):1375-1379 (1993)
	van Sprick et al., "Immunotherapeutic perspective for bispecific antibodies" Immunol Today 21(8):391-397 (Aug 2000)
	Vaswani and Hamilton, "Humanized Antibodies as Potential Therapeutic Drugs" Ann. Allergy, Asthma & Immunol. 81:105-119 (Aug 1998)
	Watson et al., "A Homing Receptor-IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venules" Journal of Cell Biology 110:2221-2229 (1990)
	Watson et al., "Neutrophil Influx into an Inflammatory Site Inhibited by a Soluble Homing Receptor-IgG Chimera" Nature 349:164-167 (Jan 10, 1991)
	Weiner et al., "A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16" Cancer Research 53:94-100 (Jan 1, 1993)
	Weiner et al., "Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII" Cancer Research 55(20):4586-4593 (Oct 15, 1995)
	Wright and Morrison, "Effect of Glycosylation on Antibody Function: Implications for Genetic Engineering" Trends in Biotechnology 15:26-32 (1997)
	Xu et al., "In vitro characterization of five humanized OKT3 effector function variant antibodies" Cellular Immunology 200(1):16-26 (2000)
C.C.	Zettlmeissl et al., "Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins" DNA and Cell Biology 9(5):347-353 (1990)

23552

PATENT TRADEMARK OFFICE

EXAMINER	<i>cs</i>	DATE CONSIDERED	6/19/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			